secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tenaya Therapeutics, Inc. (TNYA)
CIK:        0001858848
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020588
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenaya reports Q1 net loss $31.7M; cash $173.6M; TN-201 gets FDA Fast Track
---------------------------------------------------------------------------

- Cash, equivalents and marketable securities $173.6M as of March 31, 2023; runway into H1 2025.
- Net loss $31.7M ($0.43/share); R&D expense $25.6M, G&A $8.1M for Q1 2023.
- TN-201 (gene therapy for HCM) received FDA Fast Track designation; Phase 1b to start Q3 2023.
- Phase 1 dosing of TN-301 (HDAC6 inhibitor for HFpEF) complete; data expected H2 2023.
- New Scientific Advisory Board members (Drs. Seidman, Marson) and Technical Advisory Board formed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1858848/000095017023020588/0000950170-23-020588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1858848/000095017023020588/tnya-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer